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Abstract
Background: Antimicrobial resistance (AMR) in Neisseria gonorrhoeae is a major concern worldwide. It has been
recently feared that the blaTEM-1 gene is, via blaTEM-135, evolving into an extended-spectrum β-lactamase (ESBL),
which could degrade all cephalosporins including ceftriaxone. The aims of the present study were to characterize
the blaTEM genes, types of β-lactamase plasmids, the degradation of ampicillin by TEM-135 compared to TEM-1, and
to perform molecular epidemiological typing of β-lactamase-producing N. gonorrhoeae strains internationally.
Methods: β-lactamase producing N. gonorrhoeae isolates (n = 139) cultured from 2000 to 2011 in 15 countries were
examined using antibiograms, blaTEM gene sequencing, β-lactamase plasmid typing, and N. gonorrhoeae multiantigen
sequence typing (NG-MAST). Furthermore, the blaTEM gene was sequenced in the first described Toronto plasmid
(pJD7), one of the first Asian plasmids (pJD4) and African plasmids (pJD5) isolated in Canada. The degradation of
ampicillin by TEM-135 compared to TEM-1 was examined using a MALDI-TOF MS hydrolysis assay.
Results: Six different blaTEM sequences were identified (among isolates with 125 different NG-MAST STs), i.e. blaTEM-1
(in 104 isolates), blaTEM-135 (in 30 isolates), and four novel blaTEM sequences (in 5 isolates). The blaTEM-1 allele was only
found in the African and Asian plasmids, while all Rio/Toronto plasmids possessed the blaTEM-135 allele. Most interesting,
the first described gonococcal Toronto plasmid (pJD7), identified in 1984, also possessed the highly conserved blaTEM-135
allele. The degradation of ampicillin by TEM-135 compared to TEM-1 was indistinguishable in the MALDI-TOF MS
hydrolysis assay.
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Conclusions: blaTEM-135, encoding TEM-135, is predominantly and originally associated with the Rio/Toronto plasmid
and prevalent among the β-lactamase producing gonococcal strains circulating globally. blaTEM-135 does not appear, as
previously hypothesized, to have recently evolved due to some evolutionary selective pressure, for example, by the
extensive use of extended-spectrum cephalosporins worldwide. On the contrary, the present study shows that
blaTEM-135 existed in the Toronto plasmid from its discovery and that blaTEM-135 is highly conserved (not further evolved
in the past >30 years). Nevertheless, international studies for monitoring the presence of different blaTEM alleles, the
possible evolution of the blaTEM-135 allele, and the types of β-lactamase producing plasmids, remain imperative.
Keywords: Gonorrhoea, Antimicrobial resistance, blaTEM-1, blaTEM-135, TEM-1, TEM-135, Rio/Toronto plasmid,
Extended-spectrum β-lactamase (ESBL)
Background
Gonorrhoea is the most prevalent bacterial sexually trans-
mitted infection (STI) globally, according to the latest esti-
mates by the World Health Organization (WHO) [1]. No
vaccine is available and, accordingly, appropriate preven-
tion, and particularly effective diagnosis and antimicrobial
treatment are the cornerstones for control of gonorrhoea.
Neisseria gonorrhoeae has developed resistance to all anti-
microbials previously recommended for first-line empiric
monotherapy, such as penicillins, tetracyclines, macrolides
and fluoroquinolones [2-5]. Clinical resistance to the
extended-spectrum cephalosporins (ESCs) has also been
verified in the latest years in many countries [6-19].
Furthermore, the first three extensively-drug resistant
(XDR [3]) gonococcal strains were recently described;
all displayed a high-level of resistance to ceftriaxone,
the last remaining option for empiric first-line anti-
microbial monotherapy in most countries globally
[9,18,20]. All the reported decreased susceptibility and
resistance to ESCs has been due to an accumulation of
chromosomal resistance determinants [2,4,5].
In 1976 the first β-lactamase producing N. gonorrhoeae
strains, resulting in high-level resistance to penicillins
but not affecting the MICs of ESCs, were reported
[21,22]. These strains produced the traditional TEM-1
β-lactamase that hydrolyses the cyclic amide bond in the
β-lactam ring [23]. β-lactamase producing gonococcal
strains are currently widespread internationally [2,4].
The blaTEM genes are located on a family of related
β-lactamase plasmids, of which the most frequently de-
scribed have been the Asian, African, and the mainly in-
distinguishable Rio and Toronto plasmids (named based
on their epidemiological origin) [4,24-26]. However,
other types of β-lactamase producing plasmids have also
been described in gonococci, e.g. Nimes, New Zealand,
Australian and Johannesburg [4,26-28]. The Asian
plasmid has been considered to be the ancestral plas-
mid from which the other plasmids evolved through
deletions and/or insertions. Accordingly, these β-
lactamase producing plasmids may be characterised as
either deletion derivates of the Asian plasmid (Africa,
Rio/Toronto and Johannesburg) or insertion deriva-
tives of either the Asian (New Zealand) or African
(Nimes) plasmids [4,24-27].
Worryingly, the blaTEM-1 gene, encoding the TEM-1
β-lactamase, needs only a few specific single nucleotide
polymorphisms (SNPs) to evolve into a gene encoding
an extended-spectrum β-lactamase (ESBL), which could
degrade all ESCs including ceftriaxone [29-32]. The
spread of a potent ESBL, which also degrades ceftriax-
one, in the gonococcal population might rapidly result
in untreatable gonorrhoea in most settings worldwide. It
has been hypothesized that the gonococcal blaTEM-1 has
recently evolved into blaTEM-135, which originally was
identified in Salmonella enterica subsp. enterica serovar
Typhimurium [33] and might be a precursor in the evolu-
tion into an ESBL gene [29,34,35]. TEM-135 producing
gonococcal isolates have been described in 2004 and 2008
in Japan [29], from 2005 to 2007 in Thailand [34,36], and
in 2007 and 2012 in China [35]. TEM-135, which only
differs from TEM-1 by one SNP (T→C at position 539)
resulting in the amino acid alteration M182T, requires
solely one additional specific SNP to evolve into an ESBL
such as TEM-20 [29-32,34]. In those ESBLs, the M182T
alteration presumably stabilizes the active site topology
reorganized by other mutations, which collaboratively
results in the emergence of a stable ESBL [34,35,37].
However, there have been few reports, and none outside
Asia, regarding surveillance of the different types of
blaTEM genes and β-lactamase producing plasmids in the
gonococcal strains circulating worldwide.
The aims of this study were to characterize the blaTEM
genes, the types of β-lactamase plasmids, the degrad-
ation of ampicillin by TEM-135 compared to TEM-1,
and to perform molecular epidemiological typing of β-
lactamase-producing N. gonorrhoeae isolates cultured in
2000–2011 in 15 countries.
Methods
β-lactamase producing N. gonorrhoeae isolates
In total, 139 β-lactamase producing N. gonorrhoeae iso-
lates were examined, including 136N. gonorrhoeae clinical
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isolates (collected from 2000 to 2011 in 15 WHO
European (n = 40), African (n = 22), American (North and
Latin America) (n = 10), Southeast Asian (n = 33) or West-
ern Pacific (n = 31) countries) and three of the 2008 WHO
N. gonorrhoeae reference strains, i.e. WHO M (isolated in
the Philippines, 1992), WHO N (Australia, 2001), and
WHO O (Canada, 1991) [38]. All isolates were cultured
on selective culture media for 16–18 h at 37°C, in a 5%
CO2-enriched atmosphere. N. gonorrhoeae isolates were
identified using characteristic colony morphology, Gram
staining, positive oxidase test, a rapid carbohydrate
utilization test, and the Phadebact GC Monoclonal Test
(Boule Diagnostics AB, Huddinge, Sweden). All exam-
ined gonococcal isolates were cultured and stored as
part of the routine diagnostics (standard care) and no
patient identification information was used. Further-
more, to elucidate when blaTEM-135 emerged DNA from
three previously published strains was also investigated.
Those represented the first Toronto plasmid described
(pJD7 [39,40], identified in 1984), one of the first Asian
plasmids (pJD4 [39-41], identified in the late-1970s) and
one of the first African plasmids (pJD5 [39-41], identi-
fied in the late-1970s) isolated in Canada.
Antimicrobial susceptibility testing
MICs (mg/L) of the isolates for ampicillin, cefixime,
ceftriaxone, azithromycin, ciprofloxacin, and spectino-
mycin were determined using the Etest method (AB
bioMérieux, Solna, Sweden), according to the instructions
from the manufacturer. Breakpoints for susceptibility,
intermediate susceptibility and resistance in accordance to
the European Committee on Antimicrobial Susceptibility
Testing (EUCAST; www.eucast.org) were used. β-lactamase
production was identified using nitrocefin solution (Oxoid,
Basingstoke, Hants, England). The 2008N. gonorrhoeae
WHO reference strains [38] were used for quality con-
trol in all antimicrobial susceptibility testing.
β-lactamase hydrolysis assay
To examine the degradation of ampicillin by TEM-135
compared to TEM-1, a selection of six β-lactamase pro-
ducing gonococcal isolates (three blaTEM-135 and three
blaTEM-1 isolates) were investigated using a hydrolysis
assay. The non-β-lactamase producing N. gonorrhoeae
reference strain WHO F [38] was included as negative
control. All isolates were cultured on New York City
agar media plates and incubated for 16–18 h at 37°C in
a 5% CO2-enriched atmosphere. The hydrolysis assay
was performed as previously described [42] on a Micro-
flex (Bruker Daltonics, GmbH, Germany), by recording
spectra in the mass range of 0–1000 Da after incubation
for 15 minutes, 1 h, 2 h and 3 h. For calibration, the
Peptide calibration standard II (Bruker Daltonics, GmbH,
Germany) was used. The peaks utilized for calibration was
CCA [M+H] + at 190.05 Da, CCA [2 M+H] + at
379.09 Da and Bradykinin (1–7) peak [M+H] + at
757.40 Da. Generated spectra were manually examined
using the Flex Analysis 3.1 software (Bruker Daltonics,
GmbH, Germany), and peaks correlating to hydrolyzed or
intact ampicillin [42] were identified.
Plasmid DNA extraction
The QIAGEN Spin Miniprep Kit (QIAGEN, Hilden,
Germany) was used to extract and purify plasmid DNA,
according to the instructions from the manufacturer.
DNA was stored at 4°C prior to subsequent analysis.
Genomic DNA extraction
Genomic DNA was extracted using the robotized NorDiag
Bullet (NorDiag ASA, Oslo, Norway) and the BUGS’n
BEADS STI-fast kit (NorDiag ASA, Oslo, Norway), ac-
cording to the instructions from the manufacturer. DNA
was stored at 4°C prior to subsequent analysis.
Plasmid typing
Multiplex PCR was performed for β-lactamase plasmid
typing on all isolates as previously described using the
primers BL1, BL2, BL3, and BL4 [25].
Sequencing of the blaTEM gene
The entire coding region, including the signal peptide of
23 amino acids (GenBank accession number AAR25033),
of blaTEM was PCR amplified in a LightCycler real-time
PCR System (Roche Molecular Biochemicals, Mannheim,
Germany) and subsequently sequenced as previously
described [29]. Multiple-sequence alignments of nucleo-
tide and amino acid sequences were performed using
the BioEdit (version 5.0.9) software. For comparison and
numbering of the amino acid positions, all amino acid
sequences identified in the present study were compared
to sequences at the Lactamase Engineering Database
(http://www.laced.uni-stuttgart.de/) as well as at the β-
Lactamase Classification and Amino Acid Sequences
for TEM, SHV and OXA Extended-Spectrum and In-
hibitor Resistant Enzymes database (http://www.lahey.
org/Studies/). The scheme proposed by Ambler et al.
[43] was used for numbering of amino acids.
Molecular epidemiological characterisation using Neisseria
gonorrhoeae multiantigen sequence typing (NG-MAST)
Amplification and sequencing of the more variable
segments of the porB and tbpB genes examined in NG-
MAST [44,45] was performed as previously described
[46]. For assignment of porB and tbpB allele numbers as
well as NG-MAST STs, the NG-MAST website (http://
www.ng-mast.net/) was used.
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Results
Antimicrobial susceptibility of β-lactamase producing N.
gonorrhoeae isolates (n = 139) from 2000 to 2011
The majority (83.5%, n = 116/139) of isolates were resist-
ant to ampicillin and the remaining 16.5% (n = 23) had
an intermediate susceptibility to ampicillin. Furthermore,
80.6% (n = 112) and 6.5% (n = 9) of the isolates were
resistant to ciprofloxacin and azithromycin, respectively.
Only one isolate (0.7%) was resistant to cefixime (MIC =
0.25 mg/L) and no isolates were resistant to ceftriaxone
or spectinomycin.
β-lactamase plasmid types and blaTEM alleles
The African-type β-lactamase plasmid was the most com-
mon (67.6% [94/139] of isolates), followed by the Rio/
Toronto-type plasmid (18.7% [26/139] of isolates) and the
Asian-type plasmid in 13.7% (19/139) of isolates (Table 1).
No other β-lactamase plasmid types were found.
The amino acid sequences of all gonococcal TEM se-
quences identified in the present study are displayed in
Figure 1. Briefly, one-hundred and four isolates (74.8%)
possessed the blaTEM-1 allele, which was identical to the
blaTEM-1 allele in E. coli (GenBank accession number
AAR25033), and 30 (21.6%) of isolates had an identical
blaTEM-135 allele. Interestingly, all (n = 26) Rio/Toronto
plasmids contained the blaTEM-135 allele. However, the
African plasmid and Asian plasmid in one (1.1%) and
three (15.8%) isolates also contained the blaTEM-135
allele. Furthermore, four novel amino acid substitutions
in TEM were identified, that is, alterations in the signal
peptide (P14T (n = 1) and P14S (n = 2)), and in the TEM
coding sequence: E110K (n = 1) and G228S (n = 1),
which is close to the substrate binding site. All these
new blaTEM alleles were possessed by African (n = 4) or
Asian (n = 1) plasmids (Table 1).
Most interesting, the first described Toronto plasmid
(pJD7 [39,40]), isolated in 1984, also possessed the bla-
TEM-135 allele, while the Asian plasmid (pJD4 [39-41])
and African plasmid (pJD5 [39-41]), isolated in the
late-1970s, had the blaTEM-1 allele.
The mean MIC of ampicillin in TEM-135 and TEM-1
producing isolates was 16 mg/L and 12 mg/L, respect-
ively. Furthermore, the mean MIC of ceftriaxone in the
TEM-135 and TEM-1 producing isolates was identical,
that is, 0.016 mg/L. The isolates containing the novel
blaTEM alleles had also low MICs of ceftriaxone (MIC =
0.003-0.006 mg/L).
Degradation of ampicillin by TEM-135 and TEM-1
In the hydrolysis assay, the MALDI-TOF MS spectra
showed that the degradation of ampicillin by TEM-135
and TEM-1 was indistinguishable and both β-lactamases
degraded ampicillin in 15 minutes. For the non-β-
lactamase producing N. gonorrhoeae reference strain
WHO F [38], included as negative control, no hydroly-
sis was observed even after three hours of incubation
(Additional file 1: Figure S1).
Genotyping using N. gonorrhoeae multiantigen sequence
typing (NG-MAST)
In total, 125 different NG-MAST STs were identified, of
which 87 had not been previously described. The most
frequent STs were ST6058 (3.5% of isolates), ST6057
(2.9%), and ST1288 (2.2%). The majority of STs (93.6%
of the STs) were represented by one isolate, whereas five
ST were represented by two isolates. Due to the hetero-
geneity of the isolates and the many STs identified, it
was not possible to correlate any β-lactamase plasmid
type to any specific NG-MAST ST. Notably, the 30
Table 1 Type of blaTEM allele, β-lactamase producing plasmid, number of NG-MAST STs, and year and WHO Region of









blaTEM-1 (104) African (85.6), Asian (14.4) 93 2000-2011 (All Regions
a)
blaTEM-135 (30) Rio/Toronto (86.7), Asian (10),
African (3.3),
29 2000-2009 (All Regionsa)
blaTEM-P14S
b (2) African (100) 2 2008 (European)
blaTEM-P14T
b (1) Asian (100) 1 2003 (European)
blaTEM-E110K (1) African (100) 1 2003 (African)
blaTEM-G228S (1) African (100) 1 2009 (Western Pacific)
blaTEM-135
c Rio/Toronto 1984 (American)
blaTEM-1
c African Late-1970s (American)
blaTEM-1
c Asian Late-1970s (American)
aWHO European, African, American (North and Latin America), Southeast Asian and Western Pacific Region.
bAmino acid alteration in the 23 amino acids long signal peptide.
cPreviously published strains possessing the first Toronto plasmid described (pJD7 [39,40]), one of the first Asian plasmids (pJD4 [39-41]) and African plasmids
(pJD5 [39-41]) isolated in Canada.
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gonococcal isolates possessing the blaTEM-135 allele were
assigned to 29 different NG-MAST STs.
Discussion
The present study investigated the characteristics of blaTEM
genes and their association with β-lactamase plasmid type,
the degradation of ampicillin by TEM-135 compared to
TEM-1, and the molecular epidemiology of international
β-lactamase-producing N. gonorrhoeae isolates. The iso-
lates comprised a large collection of temporally (cultured
from 2000 to 2011), geographically (from 15 WHO
European, African, American (North and Latin America),
Southeast Asian or Western Pacific countries) and genet-
ically diverse (125 NG-MAST STs) gonococcal strains.
Clearly, N. gonorrhoeae strains producing TEM-1 are
widespread and all these strains carried the blaTEM-1 allele
on an African or Asian plasmid. The highly conserved
blaTEM-135 allele was predominantly found on the Rio/
Toronto plasmids, i.e. only four of the 30 identified
blaTEM-135 alleles were carried on African (n = 1) or
Asian (n = 3) plasmids. In fact, all the identified Rio/
Toronto plasmids in 26 genetically highly diverse isolates
(26 different NG-MAST STs) contained a blaTEM-135 allele
and according to our best knowledge blaTEM-1 has only
been described in one Rio/Toronto plasmid ever [34].
These results strongly indicate that the Rio/Toronto-type
plasmid is the origin of the blaTEM-135 allele. Interestingly,
in the present study the blaTEM-135 allele was also identi-
fied on the first reported Toronto plasmid (pJD7 [39,40]),
found in a gonococcal isolate from 1984. This shows that
the blaTEM-135 allele has not recently evolved and, on the
contrary, was present in the Toronto plasmid from its
discovery. This might also question the evolutionary origin
of the Rio/Toronto plasmids, i.e. that these plasmids
emerged directly through a deletion of 2273 bp in the
Asian plasmid [25,27], in which the blaTEM-135 allele is
rare internationally. Nevertheless, as shown in the
present study the blaTEM-135 allele can also be found
on African-type and Asian-type plasmids. Thus, it cannot
be excluded that those blaTEM-135 alleles might have
evolved from blaTEM-1 alleles by a SNP in those plasmids.
However, considering how conserved the gonococcal
blaTEM alleles appear to be, a more plausible explan-
ation might be that these blaTEM-135 alleles were
acquired by horizontal transfer from strains possessing
the blaTEM-135 allele on a Rio/Toronto plasmid. This
hypothesis is further supported by the lack of antimicro-
bial selective pressure for the evolution of blaTEM-1 to
blaTEM-135. Accordingly, similar MICs of ampicillin and
ceftriaxone, and of other antimicrobials, were displayed by
the TEM-135 and TEM-1 producing isolates, and the two
different TEM enzymes showed an indistinguishable deg-
radation of ampicillin in the MALDI-TOF MS hydrolysis
assay. Nevertheless, for detailed measurement of the
kinetics of the ampicillin hydrolysis appropriate kinetic
experiments (Kcat/Km) with a purified protein would
be required. All the novel blaTEM alleles found in the
present study were carried by African (four strains) or
Asian (one strain) plasmids, and none of these five isolates
had any enhanced MIC of ceftriaxone.
Figure 1 Multiple sequence alignment of TEM amino acid sequences identified in β-lactamase producing Neisseria gonorrhoeae
isolates (n = 139) cultured from 2000 to 2011 in 15 WHO European, African, American (North and Latin America), Southeast Asian or
Western Pacific countries. The amino acids 3-25 constitute the signal peptide for the mature TEM-1 enzyme. The scheme proposed by
Ambler et al. [43] was used for numbering of amino acids.
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Conclusions
blaTEM-135, encoding TEM-135, is predominantly and
originally associated with the Rio/Toronto plasmid and
prevalent among the β-lactamase producing gonococcal
strains circulating globally. blaTEM-135 does not appear,
as previously hypothesized, to have recently evolved due
to, for example, some evolutionary selective pressure by
the extended-spectrum cephalosporins. On the contrary,
blaTEM-135 existed in the Toronto plasmid from its
discovery. The present study indicates that blaTEM-135
instead is highly conserved (not further evolved in the
past >30 years). Accordingly, despite the extensive use
of extended-spectrum cephalosporins globally no add-
itional SNP has evolved in blaTEM-135. The reasons for
this remain unknown, however, both the lack of evolu-
tionary positive selection for such SNPs and a decreased
biological fitness of gonococcal strains with the result-
ing TEM alleles might be involved. Even so, only one
specific SNP added to the blaTEM-135 allele would pro-
duce an ESBL (e.g. an additional G238S alteration to
evolve into TEM-20), which would be able to degrade
all extended-spectrum cephalosporins, possibly render-
ing gonorrhoea an untreatable infection. Accordingly,
international studies for monitoring and enhancing our
understanding of, in addition to the chromosomal
ESC resistance determinants, the presence of different
blaTEM alleles, the possible evolution of the blaTEM-135
allele, and the β-lactamase producing plasmids, remain
imperative.
Additional file
Additional file 1: Figure S1. β-lactamase hydrolysis assay. MALDI-TOF
MS spectra of ampicillin after incubation with Neisseria gonorrhoeae
(β-lactamase negative, TEM-1 producing and TEM-135 producing) and
Escherichia coli ATCC 35218 (TEM-1 producing). Ampicillin alone (top) and
N. gonorrhoeae incubated in water (second from top) are also shown in
the figure. Intact ampicillin displayed the peaks of 350.4 Da, 372.4 Da and
394.4 Da while hydrolysed ampicillin displayed the peaks of 324.4 Da,
368.4 Da, 390.4 Da and 412.4 Da. The peak of 324.4 Da was observed with low
intensity also in the top-spectrum indicating a slight spontaneous hydrolysis.
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